跳至主要内容
临床试验/ACTRN12616001158459
ACTRN12616001158459招募中4 期

Comparison of the incidence and duration of hypoglycaemia assessed by Continuous Glucose Monitoring (CGM) in patients aged 65 years or older with Type 2 Diabetes (T2D), treated with Insulin Glargine (Toujeo) and Insulin Glulisine (Apidra) Versus Twice – Daily Premixed Insulin.

Western Sydney Local Health District0 个研究点目标入组 84 人开始时间: 2016年8月25日最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
入组人数
84

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Open (masking not used)

入排标准

年龄范围
65 Years 至 o limit(—)
性别
All

入选标准

  • 1- T2DM patients
  • 2- Age 65 year or older
  • 3- On twice daily premixed Insulin
  • 4-HbA1c at the time of enrolment: 6.5 to 10 %
  • 5- On stable doses of oral hypoglycemic medications in the preceding 3 months before study enrolment

排除标准

  • Exclusion Criteria:
  • 1- T1DM Patients
  • 2- Patients on long-term glucocorticoids or potential glucocorticoid treatment during the study period
  • 3-Anemia or known history of significant haematological disorders
  • 4-End stage renal disease on renal replacement therapy
  • 5-End stage liver disease
  • 6-Documented history of cognitive impairment or mental health disorders
  • 7- History of severe and recurrent documented hypoglycemia.
  • 8- Residents of high level aged care facilities
  • 9-Active malignancy (other than Squamous cell carcinoma and basal cell carcinoma).

研究者

相似试验